{"id":"W3215895013","doi":"10.1093/immadv/ltab022","title":"A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes","year":2021,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Calgary","funders":"Breakthrough T1D Canada; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Versus Arthritis; Diabetes UK; Leona M. and Harry B. Helmsley Charitable Trust; National Institute for Health and Care Research; Immune Tolerance Network; Innovative Medicines Initiative; BC Children's Hospital","keywords":"Medicine; Dosing; Internal medicine; Cohort; Maintenance therapy; Type 1 diabetes; Adverse effect; Type 2 diabetes; Clinical endpoint; Cmax; Gastroenterology; Immunology; Diabetes mellitus; Pharmacokinetics; Endocrinology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001175383,0.0001535125,0.0002511841,0.00003918216,0.00005554721,0.00004402568,0.0002622136,0.00005943791,0.00002133824],"category_scores_gemma":[0.00003105582,0.0001346556,0.00002369556,0.0003131706,0.00004000151,0.00002249216,0.00007392347,0.00007406712,0.000001099847],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001289219,"about_ca_system_score_gemma":0.00007758116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006198848,"about_ca_topic_score_gemma":0.001023159,"domain_scores_codex":[0.9990023,0.00007608024,0.0002333672,0.0003219988,0.0001192256,0.0002470312],"domain_scores_gemma":[0.999423,0.00001722898,0.0001469275,0.0002777613,0.0001117407,0.00002332223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002279391,0.01745476,0.1159782,0.00005193651,0.0005307053,0.00002005045,0.001844186,0.000128081,0.748427,0.00001803091,0.00005208165,0.1132155],"study_design_scores_gemma":[0.2648582,0.03539496,0.02017403,0.000865022,0.0001077013,0.000009699258,0.03296461,0.0001818419,0.61872,0.0002527173,0.02459417,0.001876971],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848056,0.01392862,0.00000738816,0.00001920019,0.0001099939,0.0003315653,0.00001160471,0.000006499262,0.0007795051],"genre_scores_gemma":[0.9974926,0.001794659,0.0002856379,0.00007526726,0.00001936394,0.00004505483,0.00005822283,0.0000266001,0.0002025963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2625789,"threshold_uncertainty_score":0.5491096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01257137853055862,"score_gpt":0.3053642460621322,"score_spread":0.2927928675315736,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}